Arax Advisory Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Arax Advisory Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1M	Buy	108,071 +102,514	+1,845%	+$13.9M	0.11%	196
2026 Q1	$710K	Sell	5,557 -498	-8%	-$62.2K	0.02%	519
2025 Q4	$738K	Buy	+6,055	New	+$694K	0.02%	463
2025 Q3	–	Sell	-300	Closed	-$24.9K	–	4328
2025 Q2	$24.9K	Hold	300	–	–	﹤0.01%	1558
2025 Q1	$24.3K	Hold	300	–	–	﹤0.01%	1217
2024 Q4	$27K	Buy	300 +75	+33%	+$7.27K	﹤0.01%	1099
2024 Q3	$22.2K	Hold	225	–	–	﹤0.01%	1041
2024 Q2	$20.9K	Hold	225	–	–	﹤0.01%	947
2024 Q1	$21.4K	Sell	225 -100	-31%	-$9.28K	﹤0.01%	658
2023 Q4	$29K	Hold	325	–	–	﹤0.01%	590
2023 Q3	$23.7K	Hold	325	–	–	﹤0.01%	556
2023 Q2	$27K	Sell	325 -190	-37%	-$15.9K	﹤0.01%	541
2023 Q1	$39.2K	Hold	515	–	–	0.01%	492
2022 Q4	$42.7K	Hold	515	–	–	0.01%	469
2022 Q3	$41K	Buy	+515	New	+$43.4K	0.01%	459
2020 Q4	$54K	Buy	387 +1	+0.3%	+$128	0.01%	400
2020 Q3	$43K	Buy	386 +193	+100%	+$21.6K	0.01%	401
2020 Q2	$22K	Buy	+193	New	+$19K	﹤0.01%	466
2019 Q3	–	Sell	-180	Closed	-$16K	–	613
2019 Q2	$16K	Buy	+180	New	+$15.4K	0.01%	436
2018 Q4	$18K	Hold	251	–	–	0.01%	386
2018 Q3	$24K	Buy	+251	New	+$24.3K	0.01%	386

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Arax Advisory Partners's XBI Position: Q2 2026 in Review

Arax Advisory Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1,845% in Q2 2026, buying an estimated $13.9M and bringing the position to 108,071 shares worth $17.1M. The position accounts for 0.11% of the portfolio, ranked #196.

Arax Advisory Partners first reported a position in XBI in Q3 2018 and has held it in 21 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Arax Advisory Partners held 108,071 shares of State Street SPDR S&P Biotech ETF worth $17.1M as of Q2 2026.
Arax Advisory Partners bought 102,514 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $13.9M.
State Street SPDR S&P Biotech ETF made up 0.11% of Arax Advisory Partners's portfolio in Q2 2026, its #196 holding.
Arax Advisory Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 21 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.